Athauda, Dilan

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 889

The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 383

Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes

Brauer, R., Wei, L., Ma, T., Athauda, D., Girges, C., Vijiaratnam, N., Auld, G., Whittlesea, C., Wong, I., & Foltynie, T. (2020) · Brain

Parkinson's Disease Mechanisms and TreatmentsDiabetes Treatment and Management

Cited by 233

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

Vijiaratnam, N., Girges, C., Auld, G., McComish, R., King, A., Skene, S. S., Hibbert, S., Wong, A., Melander, S., Gibson, R., et al. (2025) · The Lancet

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 181

The Impact of Type 2 Diabetes in Parkinson's Disease

Athauda, D., Evans, J., Wernick, A., Virdi, G., Choi, M. L., Lawton, M., Vijiaratnam, N., Girges, C., Ben‐Shlomo, Y., Ismail, K., et al. (2022) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 132

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

Vijiaratnam, N., Girges, C., Auld, G., Chau, M., Maclagan, K., King, A., Skene, S., Chowdhury, K., Hibbert, S., Morris, H., et al. (2021) · BMJ Open

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 84

Amyloid processing in COVID‐19‐associated neurological syndromes

Ziff, O. J., Ashton, N. J., Mehta, P. R., Brown, R., Athauda, D., Heaney, J., Heslegrave, A. J., Benedet, A. L., Blennow, K., Checkley, A. M., et al. (2022) · Journal of Neurochemistry

Long-Term Effects of COVID-19Infectious Encephalopathies and Encephalitis

Cited by 54